Speakers
--------
N/A
Monoclonal antibodies represent about half of all biologics in
development, with more than 150 compounds currently in clinical
trials. However, the attrition rate of monoclonal antibodies has been
higher than for other biologics. While early studies in pre-clinical
settings have been encouraging, the predictability and confirmation of
these same findings in humans has been difficult. The reasons for this
may include: 1) target antigen properties; 2) antibody design; 3) PK
and PD properties; 4) limited species cross reactivity (limited
availability of suitable animal models); 5) appropriate translation of
pre-clinical data to pick FIH dose; and 6) accurate identification of
patients who could benefit from target therapy. This conference will
provide a forum to review strategies and technologies that are being
used to increase the probability for success in the development of
therapeutic antibodies.